Geneoscopy's RNA-Based ColoSense Test Included in Latest National Comprehensive Cancer Network (NCCN) Guidelines
ST. LOUIS--(BUSINESS WIRE)-- Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that its ColoSense® test has been included in the National Comprehensive Cancer Network® (NCCN) Guidelines for Colorectal Cancer (CRC) Screening as a first-line test for average-risk patients, supporting its role as a screening alternative for individuals aged 45 years and older. ColoSense is a noninvasive stool-based test for detecting CRC and advanced adenomas, and is the only FDA-approved screening test utilizing stool RNA biomarkers, which are not subject to age-related methylation. 1,2
The NCCN Guidelines are comprehensive, evidence-based recommendations to support the prevention, diagnosis, and treatment of more than 97% of cancers affecting patients in the United States. They are regularly updated to reflect the latest scientific evidence and improve the quality and consistency of cancer care.
'The NCCN Guidelines are among the most trusted clinical resources in oncology, and the addition of ColoSense is a powerful validation of its clinical performance,' said Erica Barnell, M.D., Ph.D., Chief Science and Medical Officer of Geneoscopy. 'As the first and only FDA-approved stool RNA screening test for colorectal cancer, this affirms the scientific rigor behind our technology and reinforces the importance of noninvasive modalities in expanding access and improving screening compliance, especially among populations less likely to undergo colonoscopy.'
ColoSense's inclusion in the NCCN Guidelines is based on data from Geneoscopy's CRC-PREVENT pivotal study, which was published in the Journal of the American Medical Association (JAMA). 3 Unlike traditional centralized trials, in which patients are typically already engaged in healthcare screening programs, nearly two-thirds of CRC-PREVENT participants had never undergone CRC screening or scheduled a colonoscopy at the time of enrollment. The study demonstrated ColoSense's ability to detect CRC with 94% sensitivity, identifying 100% of CRC in Stage I. Additionally, ColoSense detected 46% of advanced adenomas, when the disease is most preventable.
'The NCCN Guidelines heavily impact both the clinical adoption and insurance coverage of screening tests,' said Matt Sargent, Chief Commercial Officer of Geneoscopy. 'Achieving this milestone as a first-line test marks a pivotal step forward in our mission to bring ColoSense to market as an accurate, accessible screening solution for millions of Americans. NCCN guideline inclusion also positions ColoSense for future inclusion in other major guidelines.'
About ColoSense
ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.
A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA) in October 2023. For more information, visit www.colosense.com.
About Geneoscopy, Inc.
Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
References
Ahlquist, D. A., Taylor, W. R., Yab, T. C., Devens, M. E., Mahoney, D. W., Boardman, L. A., Thibodeau, S. N., Zou, H., Michael, D., Berger, B. M., & Lidgard, G. P. (2012). Abstract 3572: Methylated gene marker levels in stool: Effects of demographic, drug, and body mass and other patient characteristics. Cancer Research, 72(8_Supplement), 3572–3572. https://doi.org/10.1158/1538-7445.am2012-3572
Ahlquist DA, Taylor WR, Yab TC, Devens ME, Mahoney DW, et al. (2012) Aberrantly Methylated Gene Marker Levels in Stool: Effects of Demographic, Exposure, Body Mass, and Other Patient Characteristics. J Mol Biomark Diagn 3:133. doi:10.4172/2155-9929.1000133
Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget Stool RNA Test for Colorectal Cancer Screening. JAMA. 2023;330(18):1760–1768. doi:10.1001/jama.2023.22231
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
CDC Vaccine Advisors To Vote On Thimerosal In Flu Shots. Here's What To Know About Thimerosal
ATLANTA, GA - OCTOBER 05: A podium with the logo for the Centers for Disease Control and Prevention ... More at the Tom Harkin Global Communications Center on October 5, 2014 in Atlanta, Georgia. (Photo by Kevin C. Cox/Getty Images) The CDC's Advisory Committee on Immunization Practices is set to vote later this week on the issue of thimerosal in flu vaccines. What exactly is thimerosal and is it actually harmful for people that take vaccines containing the substance? Thimerosal is a mercury-based organic preservative that historically was put in several vaccines in low quantities in order to prevent the growth of harmful bacteria and fungi, particularly when multi-dose vials were used. Vaccines can become accidentally contaminated, as may occur with multiple needle punctures with multi-dose vials. Before the late 1990's, infants were recommended to receive three vaccines that contained thimerosal- hepatitis B, Haemophilus influenzae type b and diphtheria-tetanus-acellular pertussis. There are no known health risks associated with thimerosal at the concentrations used in vaccines, according to the FDA. Secretary of Health and Human Services Robert F. Kennedy Jr. disagrees. In his 2014 book, he states (as reported in Politico), 'there is a virtually unanimous scientific consensus among the hundreds of research scientists who have published peer-reviewed articles in the field that Thimerosal is immensely toxic to brain tissue.' Thimerosal, as a preservative gets metabolized as ethylmercury, which is distinct from the more toxic methylmercury. In large doses, both compounds can be toxic to the brain and kidney, resulting in tremors, memory loss, mood swings, depression, protein in the urine and kidney damage. However, ethylmercury poses a significantly decreased risk for humans because it has a much shorter half-life of less than week compared to methylmercury, which has a half-life of 1.5 months according to the World Health Organization. Ethylmercury is removed from the body fast and actively excreted into the gut, as oppose to methylmercury that can accumulate in the body and result in potential toxic effects. In 1999, because of scientific uncertainty at the time and theoretical concerns about thimerosal, the preservative was removed from nearly all childhood vaccines as a precautionary measure per the FDA, not because it was shown to cause any harm. The only childhood vaccine that still contains thimerosal in some formulations is the flu vaccine. Part of the reason thimerosal was removed from childhood vaccines was because an infant in the early 1990s receiving childhood vaccines could be exposed to a cumulative dose of mercury as high as 187.5 micrograms by the age of 6 months, which exceeded the guidelines put forth by the EPA, but not the WHO. Even at a dose of 187.5 micrograms of ethylmercury, no studies have shown adverse health effects or harm to humans, other than local skin reactions at the injection site of the vaccine, as shown in a study published in the journal Pediatrics. Despite what Secretary of HHS Kennedy has suggested, thimerosal has not been shown to cause autism. In fact both the FDA and multiple peer-reviewed scientific studies have asserted and shown no link between thimerosal use in vaccines and autism. The use of thimerosal in U.S. FDA licensed vaccines has significantly declined because of reformulations and the availability of vaccines in single-dose containers. Currently, a couple of flu vaccines are formulated to contain thimerosal, although the majority of flu vaccines that currently exist do not contain thimerosal. The ACIP will convene later this week to hold a vote on the status of thimerosal on vaccines. Even if completely removed from the flu vaccine, the vaccine will not 'become' safer, as decades of research has already shown thimerosal to be safe and effective as a preservative. Experts warn that holding the vote could cast doubt on vaccine uptake. Dr. Jeremy Faust, Editor-in-Chief of MedPage Today, writes, 'Elevating this debunked myth to national policy lends credence to misinformation, and sets the stage for other actions that may undermine vaccine confidence in the United States.'
Los Angeles Times
5 hours ago
- Los Angeles Times
Early-Stage Technology Disruptions and Trends Set to Define the Future of Business Systems
Researchers point to technologies addressing GenAI-enabled code architecture, disinformation security and surface asset management as the most likely to be widely adopted by businesses by 2030, while leaders find themselves reassessing cloud usage and not overlooking the ever-growing need for effective cybersecurity solutions Through its research and surveys of C-suiters, Gartner, Inc. has identified the most likely emerging technology disruptions that will impact businesses and define the future of business systems. Technology leaders are clearly prioritizing these over the next five years, as they present competitive opportunities in the near term and will eventually grow to become standard throughout businesses. 'Technology leaders must take action now to gain a first-mover advantage with these technologies,' said Bill Ray, distinguished VP analyst at Gartner. 'Innovative advancements like generative AI-enabled code architecture, disinformation security and Earth intelligence will provide the differentiation needed to help enterprises pull ahead of the pack in terms of data and product offerings.' Each disruptor is significant in its own right, but in combination, they start to define broader emerging solutions to new business practices. For example, advancing GenAI technologies will spawn new solutions around Earth intelligence and business simulation, spur the expansive growth of domainspecific language models and lead to higher functioning tools. GenAI solutions systems using free-form text and multimedia inputs/outputs will displace the conventional form-oriented sequential UI in established enterprise applications and enable new user scenarios. 'To remain competitive, traditional enterprise application software vendors will need to refactor applications to serve composable GenAI solutions that are invoked on demand via textual and multimodal prompts,' said Ray Valdes, VP analyst at Gartner. Because of this, Gartner predicts that by 2029, more than 50% of user interactions linked to enterprise business processes will leverage large language models to bypass the UI layer in traditional enterprise applications, up from less than 5% today. Disinformation security is an emerging discipline focused on threats from outside the corporate-controlled network. It includes a suite of technologies, such as deepfake detection, impersonation prevention and reputation protection, which can address disinformation to help enterprises discern trust, protect their brand and secure their online presence. Gartner predicts that by 2030, at least half of enterprises will have adopted products or services to address disinformation security, up from less than 5% in 2024. 'Disinformation attacks use external infrastructure, like social media, and originate from areas with limited legal oversight,' said Alfredo Ramirez IV, senior director analyst at Gartner. 'Tech leaders must add 'disinformation-proofing' to products by using AI/machine learning for content verification and data provenance tracking to help users discern the truth.' Gartner predicts that by 2028, 80% of major Earth surface assets globally will be monitored by active satellites. Earth intelligence tech uses AI to analyze satellite, aerial and ground data to monitor Earth's assets and activities, providing insights for decision-making. 'That doesn't mean maps and charts. Earth intelligence is delivering numbers on global nickel production, theme park revenue and the health of wheat crops, to name just a few,' said Ray. Given the breadth of applications, Earth intelligence is applicable to all industries and enterprises. Defense has been the first adopter, but improvements in the quality of data and analysis techniques have rapidly expanded the use cases. The Earth intelligence market is now divided between those who capture the data, those who interpret and analyze it and those who generate industry-specific insights. 'Earth intelligence applies to every business,' said Ray. 'Enterprises can gain an early advantage by creatively and strategically applying Earth intelligence to significantly enhance specific functionalities of existing systems or to compete via new net capabilities.' In a separate research report, Gartner has also announced the top trends shaping the future of cloud adoption over the next four years. These include cloud dissatisfaction, AI/machine learning (ML), multicloud, sustainability, digital sovereignty and industry solutions. Joe Rogus, director, advisory at Gartner, said, 'These trends are accelerating the shift in how cloud is transforming from a technology enabler to a business disruptor and necessity for most organizations. Over the next few years, cloud will continue to unlock new business models, competitive advantages and ways of achieving business missions.' Cloud adoption continues to grow, but not all implementations succeed. Gartner predicts 25% of organizations will have experienced significant dissatisfaction with their cloud adoption by 2028, due to unrealistic expectations, suboptimal implementation and/or uncontrolled costs. To remain competitive, enterprises need a clear cloud strategy and effective execution. Gartner research indicates that those who have successfully addressed upfront strategic focus by 2029 will find their cloud dissatisfaction will decrease. Gartner also predicts 50% of cloud computing resources will be devoted to AI workloads by 2029, up from less than 10% today. 'This all points to a fivefold increase in AI-related cloud workloads by 2029,' said Rogus. 'Now is the time for organizations to assess whether their data centers and cloud strategies are ready to handle this surge in AI and ML demand. In many cases, they might need to bring AI to where the data is to support this growth.' Many organizations that have adopted multicloud architecture find connecting to and between providers a challenge. This lack of interoperability between environments can slow cloud adoption, with Gartner predicting more than 50% of organizations will not get the expected results from their multicloud implementations by 2029. Gartner recommends identifying specific use cases and planning for distributed apps and data in the organization that could benefit from a cross-cloud deployment model. This enables workloads to operate collaboratively across different cloud platforms, as well as different onpremises and colocation facilities. AI adoption, tightening privacy regulations and geopolitical tensions are also driving demand for sovereign cloud services. Organizations will be increasingly required to protect data, infrastructure and critical workloads from control by external jurisdictions and foreign government access. Gartner predicts over 50% of multinational organizations will have digital sovereign strategies by 2029, up from less than 10% today. 'As organizations proactively align their cloud strategies to address digital sovereignty requirements, there are already a wide range of offerings that will support them,' said Rogus. 'However, it's important they understand exactly what their requirements are, so they can select the right mix of solutions to safeguard their data and operational integrity.' With all the talk of businesses onboarding GenAI and other emerging technology solutions, it's easy to overlook cybersecurity tools. CEOs, however, are not forgetting to lock the proverbial door. Gartner's research has shown that a whopping 85% of CEOs surveyed say that cybersecurity is critical for business growth moving forward. In a survey of 456 CEOs and other senior business executives, 61% of CEOs are concerned about cybersecurity threats, driven in large part by AI's growing role in commercial activity and the political debates about the sourcing and use of advanced technologies. As risk thresholds shift, they view cybersecurity as a key driver. 'Cybersecurity is no longer just about protection; it's a critical driver for business growth,' said David Furlonger, distinguished vice president analyst and Gartner fellow. 'With 85% of CEOs recognizing its importance, security leaders have a unique opportunity to demonstrate the value of cybersecurity investments not only in safeguarding assets but also in enabling strategic business objectives.' 'Effective communication is key,' said Furlonger. 'CEOs should highlight the role of security leaders in both protecting the business and enhancing cybersecurity to drive growth. This involves, for example, assessing risks in foreign markets and intellectual property protection. Security leaders are positioned to significantly influence value generation, and they should communicate how cybersecurity aids enterprise growth.' With regulatory changes and cybersecurity threats challenging competitiveness, CEOs said they see a direct linkage between cybersecurity capabilities and enterprise growth. Meanwhile, C-suiters' comfort level with AI is far from established at this point. Only 44% of CIOs are deemed by their CEOs to be 'AI-savvy' according to the Gartner data. The survey revealed that 77% of CEOs believe that AI is indeed ushering in a new business era, yet they feel their organization's leading technology experts lack the knowledge and capabilities to support, drive or accelerate business outcomes in this evolving landscape. 'We have never seen such a disproportionate gap in CEOs' impressions about technological disruption,' said Furlonger. 'AI is not just an incremental change from digital business. AI is a step change in how business and society work. A significant implication is that if savviness across the C-suite is not rapidly improved, competitiveness will suffer and corporate survival will be at stake.' CEOs perceive even the CIO, chief information security officer (CISO) and chief data officer (CDO) as lacking AI savviness. CEOs highlighted that the top two limiting factors impacting AI's deployment and use are the inability to hire adequate numbers of skilled people and an inability to calculate value or outcomes. 'CEOs have shifted their view of AI from just a tool to a transformative way of working,' said Jennifer Carter, principal analyst at Gartner. 'This change has highlighted the importance of upskilling. As leaders recognize AI's potential and its impact on their organizations, they understand that success isn't just about hiring new talent. Instead, it's about equipping their current employees with the skills needed to seamlessly incorporate AI into everyday tasks.'
Forbes
7 hours ago
- Forbes
Safer Sunscreens: Selecting Healthy and Reef-Safe Products
Choosing sunscreen that is healthy and reef-safe can be challenging. As summer temperatures soar and we flock to beaches, pools, and outdoor recreation areas, choosing the right sunscreen is important but challenging. On one hand, the American Cancer Society estimates that more than 100,000 Americans will be diagnosed with invasive melanoma in 2025. On the other hand, some sunscreen ingredients are linked to hormone disruption and other health harms. And then there's the fact that approximately 14,000 tons of sunscreen wash into coral reefs annually, contributing to the destruction of marine ecosystems. How can our sunscreen choices balance these concerns? Mineral Sunscreens Are Safer Than Chemical Sunscreens Under current FDA guidelines, only two active ingredients are classified as "Generally Recognized As Safe and Effective" (GRASE): zinc oxide and titanium dioxide. These mineral-based compounds work by creating a physical barrier on the skin that reflects and scatters ultraviolet radiation away from the body. In contrast, the FDA has requested additional safety data for 12 chemical sunscreen ingredients, including avobenzone, oxybenzone, octinoxate, and octocrylene. This is because there is growing evidence that these chemicals can be absorbed through the skin and may pose health risks. Mineral sunscreens are also more reef-safe. Oxybenzone and octinoxate, two of the most common chemical sunscreen ingredients, have been identified as primary drivers of coral bleaching, a process that strips corals of their life-sustaining algae and leaves them vulnerable to disease and death. These chemicals also disrupt the endocrine systems and brains of fish. Mineral-based alternatives like zinc oxide and titanium dioxide pose no known harm to coral reefs or other marine life. Sunscreen Lotions Are Safer Than Sprays And Mists While spray sunscreens are convenient, they may be the worst choice for both human health and the environment. This is because aerosol delivery systems release significant quantities of sunscreen into the air rather than onto skin. These airborne particles can travel considerable distances before settling on surfaces, potentially contaminating areas far from where we applied the sunscreen. When used near beaches, lakes, or other water bodies, spray sunscreens directly introduce chemicals into aquatic environments without the intermediate step of skin contact. There is also a risk of inadvertent inhalation of spray sunscreen particles, especially when products are used on children. Additionally, achieving adequate coverage with spray formulations proves challenging, often resulting in uneven protection and increased sunburn risk. Picking The Best Sunscreens How can you tell which sunscreens are safe for your health and for reefs? Check the label. The Surfrider Foundation's "HEL list" (Harmful Elements List) provides a clear framework for ingredients to avoid: oxybenzone, octinoxate, octocrylene, 4-methylbenzylidene camphor, PABA, parabens, triclosan, microplastics like 'exfoliating beads,' and nanoparticles. The organization emphasizes avoiding nano-sized zinc oxide and titanium dioxide particles, which may pose risks to marine ecosystems despite their mineral origin. If you're looking for specific brand recommendations, here are some expert guides: There are also helpful shopping resources like Clearya. This free platform functions as both a browser extension and mobile app, automatically scanning product ingredients against comprehensive databases of potentially harmful chemicals. You can scan sunscreens while shopping on major retail platforms like Amazon, Sephora, and Walmart, receiving instant feedback on product safety. Beyond Sunscreen: Comprehensive Sun Safety Strategies Although sunscreen is effective, it's important to remember that physical barriers are our first line of defense against UV radiation. Wide-brimmed hats provide excellent protection for faces, necks, and ears—areas often inadequately covered by sunscreen application. Lightweight, long-sleeved shirts and pants offer extensive coverage while remaining comfortable in hot weather. Avoiding direct sun exposure during peak intensity hours (typically 10 AM to 4 PM) can also significantly reduce overall radiation exposure. Seeking shade whenever possible provides natural protection. So, what's the takeaway here? Prioritize mineral sunscreens with zinc oxide and titanium dioxide, choose lotion formulations over sprays, and prioritize comprehensive sun safety strategies that protect both our health and the precious marine ecosystems.
